ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $83.53, for a total value of $1,670,600.00. Following the sale, the director now directly owns 314,800 shares in the company, valued at approximately $26,295,244. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ResMed Inc. (NYSE:RMD) opened at $82.72 on Friday. The company has a market capitalization of $11,663.08, a P/E ratio of 28.64, a price-to-earnings-growth ratio of 1.82 and a beta of 0.79. ResMed Inc. has a 12-month low of $57.45 and a 12-month high of $87.81. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.86 and a current ratio of 4.72.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting the consensus estimate of $0.66. ResMed had a return on equity of 21.53% and a net margin of 16.58%. The company had revenue of $523.66 million for the quarter, compared to analyst estimates of $506.08 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The firm’s revenue was up 12.5% compared to the same quarter last year. equities analysts expect that ResMed Inc. will post 3.01 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be paid a $0.35 dividend. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 annualized dividend and a dividend yield of 1.69%. ResMed’s dividend payout ratio (DPR) is currently 56.68%.

TRADEMARK VIOLATION NOTICE: “Peter C. Farrell Sells 20,000 Shares of ResMed Inc. (RMD) Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/10/peter-c-farrell-sells-20000-shares-of-resmed-inc-rmd-stock.html.

Hedge funds have recently made changes to their positions in the business. YorkBridge Wealth Partners LLC grew its stake in shares of ResMed by 4.9% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,476 shares of the medical equipment provider’s stock valued at $115,000 after purchasing an additional 69 shares during the last quarter. Creative Planning grew its stake in shares of ResMed by 97.1% in the 2nd quarter. Creative Planning now owns 1,671 shares of the medical equipment provider’s stock valued at $130,000 after purchasing an additional 823 shares during the last quarter. Toronto Dominion Bank grew its stake in shares of ResMed by 12.8% in the 2nd quarter. Toronto Dominion Bank now owns 1,740 shares of the medical equipment provider’s stock valued at $135,000 after purchasing an additional 197 shares during the last quarter. Huntington National Bank purchased a new position in shares of ResMed in the 2nd quarter valued at approximately $156,000. Finally, BB&T Investment Services Inc. purchased a new position in shares of ResMed in the 2nd quarter valued at approximately $214,000. Institutional investors own 60.00% of the company’s stock.

RMD has been the topic of several research analyst reports. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Thursday, October 12th. Northland Securities reissued a “sell” rating and set a $55.00 target price on shares of ResMed in a research report on Friday, October 27th. Needham & Company LLC reissued a “sell” rating on shares of ResMed in a research report on Friday, September 8th. Barclays PLC raised their target price on ResMed from $65.00 to $68.00 and gave the stock an “underweight” rating in a research report on Monday, September 25th. Finally, Bank of America Corporation lowered ResMed from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $67.57.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Insider Buying and Selling by Quarter for ResMed (NYSE:RMD)

Receive News & Stock Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related stocks with our FREE daily email newsletter.